Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

E-resources

PDF

Peer reviewed Open access

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

Griffin, M. Pamela; Yuan, Yuan; Takas, Therese; Domachowske, Joseph B; Madhi, Shabir A; Manzoni, Paolo; Simões, Eric A.F; Esser, Mark T; Khan, Anis A; Dubovsky, Filip; Villafana, Tonya; DeVincenzo, John P

New England journal of medicine/The New England journal of medicine, 07/2020, Volume: 383, Issue: 5

Journal Article

Nirsevimab, a monoclonal antibody with an extended half-life, is designed to protect infants from respiratory syncytial virus disease after a single intramuscular dose. This placebo-controlled trial involving 1447 preterm infants at 164 sites in 23 countries assessed the effectiveness of nirsevimab over 150 days after the dose was administered.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme